Ambiq Micro CTO Scott Hanson sells $3.28m in AMBQ stock

Scott McLean Hanson, Chief Technology Officer and a Director at Ambiq Micro, Inc. (NASDAQ:AMBQ), recently sold company shares totaling over $3.28 million, according to a regulatory filing dated August 28, 2026. These transactions occurred on August 26 and 27, 2026, and involved the sale of common stock following the exercise of stock options. The sales come as AMBQ stock trades at $57.34, down from its 52-week high of $91.61, though the company has delivered a strong 101% year-to-date return. According to InvestingPro analysis, the stock appears overvalued at current levels, placing it among companies on the Most Overvalued list.

On August 26, Mr. Hanson acquired 37,500 shares of common stock through option exercises at a price of $8.12 per share, amounting to $304,500. He then sold 27,500 of these shares at a weighted average price of $59.5807, with individual sale prices ranging from $59.00 to $59.90 per share. This sale generated approximately $1,638,469.25.

The following day, August 27, Mr. Hanson acquired an additional 27,500 shares of common stock through option exercises, also at $8.12 per share, for a total of $223,300. He proceeded to sell 22,590 shares at a weighted average price of $59.6916, with prices ranging from $59.11 to $60.10 per share, yielding approximately $1,348,369.30. On the same day, he sold another 4,910 shares at a weighted average price of $60.321, with prices ranging from $60.11 to $60.78 per share, for approximately $296,239.11.

In total, Mr. Hanson acquired common stock valued at $527,799 through option exercises and sold 54,910 shares of common stock for a total value of $3,283,078 across the two days. Following these reported transactions, Mr. Hanson beneficially owns 221,226 shares of Ambiq Micro common stock directly. He also holds derivative securities, including stock options, which allow him to purchase additional shares. For deeper insights into AMBQ’s valuation and insider activity trends, InvestingPro offers 11 additional ProTips and comprehensive analysis through its Pro Research Report, available for this and 1,400+ other US equities.

In other recent news, Ambiq Micro reported impressive second-quarter earnings, with revenue soaring by 89.7% from the previous year to reach $33.9 million. This marks the company’s fifth consecutive quarter of sequential growth, driven largely by the increasing demand for edge AI chips. The company also revised its full-year sales outlook upward to approximately $135 million. UBS and BofA Securities both adjusted their price targets for Ambiq Micro, with UBS raising it to $73 and BofA to $75, citing strong demand and growth in edge-AI applications. UBS maintained a Neutral rating, while BofA kept an Underperform rating despite the positive developments. The company’s management highlighted accelerating momentum in wearables and newer applications in medical, industrial, and smart-home sectors. Additionally, BofA noted that the demand currently exceeds the available supply across various components, reinforcing their view on the company’s unit-led growth. These developments reflect a robust market position for Ambiq Micro as it continues to capitalize on the edge-AI demand.